S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Stock market today: Wall Street rises in premarket as bond markets stabilize and earnings roll in
Predicting a Bear Market: 7 Signs and Why it's Tough to Do
Abbott Laboratories Outlook is Healthy: Buy the Dip
Closing prices for crude oil, gold and other commodities
United Airlines Soars on Earnings Beat
CSX profit drops 10% despite railroad delivering 3% more freight in first quarter
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Stock market today: Wall Street rises in premarket as bond markets stabilize and earnings roll in
Predicting a Bear Market: 7 Signs and Why it's Tough to Do
Abbott Laboratories Outlook is Healthy: Buy the Dip
Closing prices for crude oil, gold and other commodities
United Airlines Soars on Earnings Beat
CSX profit drops 10% despite railroad delivering 3% more freight in first quarter
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Stock market today: Wall Street rises in premarket as bond markets stabilize and earnings roll in
Predicting a Bear Market: 7 Signs and Why it's Tough to Do
Abbott Laboratories Outlook is Healthy: Buy the Dip
Closing prices for crude oil, gold and other commodities
United Airlines Soars on Earnings Beat
CSX profit drops 10% despite railroad delivering 3% more freight in first quarter
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Stock market today: Wall Street rises in premarket as bond markets stabilize and earnings roll in
Predicting a Bear Market: 7 Signs and Why it's Tough to Do
Abbott Laboratories Outlook is Healthy: Buy the Dip
Closing prices for crude oil, gold and other commodities
United Airlines Soars on Earnings Beat
CSX profit drops 10% despite railroad delivering 3% more freight in first quarter

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cellect Biotechnology Ltd. stock logo
APOP
Cellect Biotechnology
$13.17
+0.4%
$11.51
$6.64
$35.52
$12.87M1.87479,845 shs17,400 shs
ASNB
EKIMAS
$0.61
$0.55
$0.55
$1.75
$3.54M0.373,162 shsN/A
Dynatronics Co. stock logo
DYNT
Dynatronics
$0.59
+5.4%
$0.46
$0.37
$1.62
$2.69M0.451.31 million shs1.40 million shs
ECIA
Encision
$0.70
$0.54
$0.25
$0.75
$8.24M0.37254 shsN/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
$3.57
+1.7%
$3.74
$2.70
$11.82
$6.97M2.2614,097 shs10,685 shs
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cellect Biotechnology Ltd. stock logo
APOP
Cellect Biotechnology
0.00%0.00%0.00%0.00%0.00%
ASNB
EKIMAS
0.00%0.00%+1.67%+24.49%-22.78%
Dynatronics Co. stock logo
DYNT
Dynatronics
+6.36%+46.29%+35.70%+4.48%-58.54%
ECIA
Encision
0.00%0.00%+52.84%+52.17%+79.49%
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
+1.71%-3.25%-7.51%+12.97%-68.80%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cellect Biotechnology Ltd. stock logo
APOP
Cellect Biotechnology
N/AN/AN/AN/AN/AN/AN/AN/A
ASNB
EKIMAS
N/AN/AN/AN/AN/AN/AN/AN/A
Dynatronics Co. stock logo
DYNT
Dynatronics
1.8511 of 5 stars
3.05.00.00.02.50.00.6
ECIA
Encision
N/AN/AN/AN/AN/AN/AN/AN/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cellect Biotechnology Ltd. stock logo
APOP
Cellect Biotechnology
N/AN/AN/AN/A
ASNB
EKIMAS
N/AN/AN/AN/A
Dynatronics Co. stock logo
DYNT
Dynatronics
2.00
Hold$3.80549.57% Upside
ECIA
Encision
N/AN/AN/AN/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/AN/AN/AN/A

Current Analyst Ratings

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cellect Biotechnology Ltd. stock logo
APOP
Cellect Biotechnology
N/AN/AN/AN/A$4.77 per shareN/A
ASNB
EKIMAS
N/AN/AN/AN/A$0.03 per shareN/A
Dynatronics Co. stock logo
DYNT
Dynatronics
$40.61M0.07N/AN/A$2.19 per share0.27
ECIA
Encision
$7.35M1.12N/AN/A$0.21 per share3.33
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
$5.90M1.20N/AN/A$13.18 per share0.27

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cellect Biotechnology Ltd. stock logo
APOP
Cellect Biotechnology
-$5.62MN/A0.00N/AN/AN/AN/AN/A
ASNB
EKIMAS
-$290KN/A0.00N/AN/A-7,902.31%-5,274.01%N/A
Dynatronics Co. stock logo
DYNT
Dynatronics
-$4.97M-$1.38N/AN/A-14.13%-54.88%-16.14%5/9/2024 (Estimated)
ECIA
Encision
-$320K-$0.04N/AN/A-6.51%-18.97%-10.50%6/20/2024 (Estimated)
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
-$6.53M-$6.23N/AN/A-110.64%-31.31%-29.32%5/1/2024 (Estimated)

Latest APOP, ECIA, DYNT, NURO, and ASNB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
2/22/2024Q4 2023
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/A-$1.43-$1.43-$1.43N/A$1.32 million    
2/14/2024Q3 2024
ECIA
Encision
N/A-$0.02-$0.02-$0.02N/A$1.58 million
2/7/2024Q2 2024
Dynatronics Co. stock logo
DYNT
Dynatronics
N/A-$0.27-$0.27-$0.27N/A$8.15 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cellect Biotechnology Ltd. stock logo
APOP
Cellect Biotechnology
N/AN/AN/AN/AN/A
ASNB
EKIMAS
N/AN/AN/AN/AN/A
Dynatronics Co. stock logo
DYNT
Dynatronics
N/AN/AN/AN/AN/A
ECIA
Encision
N/AN/AN/AN/AN/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cellect Biotechnology Ltd. stock logo
APOP
Cellect Biotechnology
N/A
3.01
3.01
ASNB
EKIMAS
N/A
0.12
0.12
Dynatronics Co. stock logo
DYNT
Dynatronics
0.21
1.41
0.67
ECIA
Encision
0.11
2.55
1.08
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/A
16.80
15.55

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Cellect Biotechnology Ltd. stock logo
APOP
Cellect Biotechnology
4.84%
ASNB
EKIMAS
N/A
Dynatronics Co. stock logo
DYNT
Dynatronics
4.18%
ECIA
Encision
8.20%
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
19.40%

Insider Ownership

CompanyInsider Ownership
Cellect Biotechnology Ltd. stock logo
APOP
Cellect Biotechnology
N/A
ASNB
EKIMAS
7.80%
Dynatronics Co. stock logo
DYNT
Dynatronics
9.10%
ECIA
Encision
40.87%
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
4.40%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Cellect Biotechnology Ltd. stock logo
APOP
Cellect Biotechnology
2,020977,000N/ANot Optionable
ASNB
EKIMAS
115.80 million5.35 millionNot Optionable
Dynatronics Co. stock logo
DYNT
Dynatronics
1544.88 million4.44 millionNot Optionable
ECIA
Encision
3111.78 million6.96 millionNot Optionable
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
261.99 million1.84 millionNot Optionable

APOP, ECIA, DYNT, NURO, and ASNB Headlines

SourceHeadline
NeuroMetrix (NASDAQ:NURO) Coverage Initiated by Analysts at StockNews.comNeuroMetrix (NASDAQ:NURO) Coverage Initiated by Analysts at StockNews.com
americanbankingnews.com - April 18 at 2:30 AM
NeuroMetrix (NASDAQ:NURO) Receives New Coverage from Analysts at StockNews.comNeuroMetrix (NASDAQ:NURO) Receives New Coverage from Analysts at StockNews.com
americanbankingnews.com - April 10 at 2:50 AM
NeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral NeuropathyNeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy
globenewswire.com - March 14 at 9:00 AM
NeuroMetrix, Inc.: NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell FibromyalgiaNeuroMetrix, Inc.: NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell Fibromyalgia
finanznachrichten.de - March 13 at 10:19 PM
NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell® FibromyalgiaNeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell® Fibromyalgia
globenewswire.com - March 13 at 9:00 AM
Echo Lake Capital Issues Top Ten List of Reasons Why Shai Gozani, CEO of Neurometrix Inc., Should Be FiredEcho Lake Capital Issues Top Ten List of Reasons Why Shai Gozani, CEO of Neurometrix Inc., Should Be Fired
accesswire.com - March 12 at 8:00 AM
RS Fund Management LLC: RS FUND LP Calls for Immediate Action and Capital Return in Neurometrix, Inc.RS Fund Management LLC: RS FUND LP Calls for Immediate Action and Capital Return in Neurometrix, Inc.
finanznachrichten.de - March 8 at 2:12 PM
RS FUND LP Calls for Immediate Action and Capital Return in Neurometrix, Inc.RS FUND LP Calls for Immediate Action and Capital Return in Neurometrix, Inc.
finance.yahoo.com - March 8 at 2:12 PM
Echo Lake Capital Calls for the Liquidation of Neurometrix, Inc.Echo Lake Capital Calls for the Liquidation of Neurometrix, Inc.
accesswire.com - March 4 at 8:00 AM
Google releases new open LLMs, Rivian lays off staff and Signal rolls out usernamesGoogle releases new open LLMs, Rivian lays off staff and Signal rolls out usernames
au.lifestyle.yahoo.com - February 25 at 9:19 AM
NeuroMetrix Full Year 2023 Earnings: US$6.08 loss per share (vs US$4.96 loss in FY 2022)NeuroMetrix Full Year 2023 Earnings: US$6.08 loss per share (vs US$4.96 loss in FY 2022)
finance.yahoo.com - February 24 at 12:41 PM
NeuroMetrix, Inc. (NASDAQ:NURO) Q4 2023 Earnings Call TranscriptNeuroMetrix, Inc. (NASDAQ:NURO) Q4 2023 Earnings Call Transcript
finance.yahoo.com - February 23 at 4:00 PM
NeuroMetrix, Inc.: NeuroMetrix Reports Q4 and Full Year 2023 Business HighlightsNeuroMetrix, Inc.: NeuroMetrix Reports Q4 and Full Year 2023 Business Highlights
finanznachrichten.de - February 22 at 8:37 AM
NeuroMetrix Reports Q4 and Full Year 2023 Business HighlightsNeuroMetrix Reports Q4 and Full Year 2023 Business Highlights
finance.yahoo.com - February 22 at 8:37 AM
NeuroMetrix Reports Q4 and Full Year 2023 Business HighlightsNeuroMetrix Reports Q4 and Full Year 2023 Business Highlights
globenewswire.com - February 22 at 7:00 AM
NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference CallNeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference Call
finance.yahoo.com - February 15 at 11:31 AM
NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference CallNeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference Call
globenewswire.com - February 15 at 9:00 AM
NeuroMetrix, Inc.: NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder ValueNeuroMetrix, Inc.: NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder Value
finanznachrichten.de - February 13 at 4:30 PM
NeuroMetrix Plans Strategic Options To Promote Growth, Maximize Shareholder Value; Stock DropsNeuroMetrix Plans Strategic Options To Promote Growth, Maximize Shareholder Value; Stock Drops
markets.businessinsider.com - February 13 at 4:30 PM
NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder ValueNeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder Value
finance.yahoo.com - February 13 at 10:32 AM
NeuroMetrix to Present at the Emerging Growth Conference on January 10, 2024NeuroMetrix to Present at the Emerging Growth Conference on January 10, 2024
finance.yahoo.com - January 8 at 1:17 PM
NeuroMetrix, Inc.: NeuroMetrix Reports Encouraging Results from Pilot Clinical Trial of Quell in Post-Acute COVID-19 Syndrome (Long COVID)NeuroMetrix, Inc.: NeuroMetrix Reports Encouraging Results from Pilot Clinical Trial of Quell in Post-Acute COVID-19 Syndrome (Long COVID)
finanznachrichten.de - December 12 at 1:12 PM
NeuroMetrix Reports Encouraging Results from Pilot Clinical Trial of Quell® in Post-Acute COVID-19 Syndrome (Long COVID)NeuroMetrix Reports Encouraging Results from Pilot Clinical Trial of Quell® in Post-Acute COVID-19 Syndrome (Long COVID)
finance.yahoo.com - December 12 at 1:12 PM
NeuroMetrix Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Showing that Quell® Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy (CIPN)NeuroMetrix Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Showing that Quell® Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy (CIPN)
finance.yahoo.com - December 5 at 10:09 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Cellect Biotechnology logo

Cellect Biotechnology

NASDAQ:APOP
Cellect Biotechnology Ltd. engages in the provision of regenerative medicine. Its activities include development of regenerative medicine through the development of products facilitating immune stem cell selection. The company also develops innovative technology, which allows the default stem cells by dramatically reducing of complications existing in conventional selection methods. The company was founded by Kasbian Nuriel Chirich, Shai Yarkoni, and Nadir Askenasy on August 4, 1986 and is headquartered in Kfar Saba, Israel.

EKIMAS

OTCMKTS:ASNB
EKIMAS Corp. engages in the development of polymer materials, which provide characteristics in the design and development of medical devices. Its biomaterials are used in devices that are designed for treating a range of anatomical sites and disease states. The firm's products include ChronoFlex, ChronoSil, HydroMed, HydroThane, and PolyBlend. The company was founded in 1993 and is headquartered in Las Vegas, NV.
Dynatronics logo

Dynatronics

NASDAQ:DYNT
Dynatronics Corporation, a medical device company, designs, manufactures, and sells physical therapy, rehabilitation, orthopedics, pain management, and athletic training products in the United States. The company offers orthopedic soft bracing products include cervical collars, shoulder immobilizers, arm slings, wrist and elbow supports, abdominal and lumbosacral supports, maternity supports, knee immobilizers and supports, ankle walkers and supports, plantar fasciitis splints, and cold therapy products. It also offers physical therapy and rehabilitation products, which include therapeutic modality devices comprising electrotherapy, ultrasound, phototherapy, traction, hot and cold therapy, and electrodes; and power and manually operated treatment tables, mat platforms, work tables, parallel bars, training stairs, weight racks, and other related equipment. In addition, the company manufactures and distributes clinical supplies, including exercise bands and tubing, lotions and gels, orthopedic bracings, paper products, and other related supplies. It markets its products under the Dynatron, Dynatron Solaris, Dynaheat, BodyIce, Powermatic, Bird & Cronin, Physician's Choice, Hausmann, PROTEAM, and Mammoth brands. The company sells its products to orthopedists, physical therapists, chiropractors, athletic trainers, sports medicine practitioners, clinics, hospitals, and retail distributors and equipment manufacturers. It also exports its products in Asia, Latin America, and the Middle East. Dynatronics Corporation was founded in 1979 and is headquartered in Eagan, Minnesota.

Encision

OTCMKTS:ECIA
Encision Inc., a medical device company, designs, develops, manufactures, and markets patented surgical instruments in the United States. The company provides active electrode monitoring (AEM) surgical instruments and monitors that enhance patient safety and patient outcomes in laparoscopic surgical procedures. Its AEM instruments product line comprises a range of endo-mechanical instruments, including scissors, graspers, and dissectors, as well as fixed-tip electrodes and suction-irrigation electrodes. The company also offers various handles, which are used for advanced laparoscopic procedures that incorporate stiffer shafts and ergonomic features; and AEM EndoShield 2 burn protection systems, as well as markets AEM monitor product line that is used in conjunction with AEM instruments. The company sells its products through a network of direct and independent sales representatives. Encision Inc. was incorporated in 1991 and is based in Boulder, Colorado.
NeuroMetrix logo

NeuroMetrix

NASDAQ:NURO
NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.